Hevolution Foundation to Host Panel on Healthspan Investing at 2023 BIO International Convention

-(BUSINESS WIRE)-- Hevolution Foundation, a global non-profit organization that provides grants and early-stage investments to incentivize research and entrepreneurship in healthspan science, announces its participation at the upcoming BIO International Convention, taking place at the Boston Convention Center, June 5-8, 2023. As part of its commitment to advancing healthspan research and entrepreneurship, Hevolution will be hosting a thought-provoking panel discussion, "Healthy Returns: Healthspan Investment Comes of Age."

The session, scheduled for Tuesday, June 6th at 3:00pm ET, will be moderated by William Greene, MD, Chief Investment Officer of Hevolution Foundation. Esteemed authorities from the biopharmaceutical and investment fields will serve as panelists:

• Jens Eckstein, PhD, Managing Partner at Apollo Health Ventures
• Alexander Fleming, MD, Founder and Chairman of Kinexum, and former head of metabolic disease review at the FDA
• Kristen Fortney, PhD, Founder and CEO of BioAge Labs
• Andrew Levin, MD, PhD, Managing Director at RA Capital
• John McDonald, Corporate Vice President of Global R&D Business Development at Novo Nordisk

The world is facing a demographic crisis, marked by the challenges posed by unhealthy aging. As societies age rapidly while fertility rates decline, there is a pressing need to extend the healthy years of life, also known as healthspan. This imperative also presents a unique opportunity for biopharma investors to make a substantial impact on the future of healthcare and society, and it may represent one of the biggest investment opportunities of the 21st Century.

The discussion will delve into the ongoing evolution of healthspan research from a niche field towards being a central focus of the biopharmaceutical industry, potentially driving the next wave of R&D innovation. The session will explore the promises and potential pitfalls for investors in this burgeoning sector. Additionally, panelists will address growing pains in the field and propose strategies to overcome them, unveil emerging areas of investment focus, and share their insights into the future of healthspan research and its implications for biopharma investors.

"We are excited to host this distinguished panel of experts at the BIO International Convention," commented Dr. Greene. "The discussion promises to shed light on the transformative power of healthspan investment and its potential to shape the future of healthcare. We invite BIO attendees to join us as we explore the unique opportunities and challenges in this rapidly evolving field."